Edition:
United States

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

26.00USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$26.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
396,015
52-wk High
$55.94
52-wk Low
$25.41

Select another date:

Wed, Nov 29 2017

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

BRIEF-Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company

* MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY Source text for Eikon: Further company coverage:

BRIEF-Medicines Co names Fred Eshelman executive chairman

* The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors

BRIEF-SymBio Pharmaceuticals says arbitration against The Medicines Company

* Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for the exclusive rights to develop and commercialize the patient-controlled pain management drug "SyB P-1501" (or "IONSYS") in Japan

BRIEF-The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran

* The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran

BRIEF-The Medicines Company reports third-quarter 2017 business and financial results

* The Medicines Company reports third-quarter 2017 business and financial results

BRIEF-The Medicines Company announces FDA approval of Vabomere

* The Medicines Company announces FDA approval of Vabomere (meropenem and vaborbactam)

FDA approves Medicines Co's urinary tract infection drug

The U.S. Food and Drug Administration said on Tuesday it has approved Medicines Co's antibacterial drug for patients with complicated urinary tract infections (cUTI).

BRIEF-Medicines Co reports Q2 GAAP loss per share $5.52 from continuing operations

* The Medicines Company reports second quarter 2017 business and financial results

BRIEF-The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam stopped early for superior benefit-risk compared to best available therapy for CRE

* The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE

Select another date: